Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
| ▸ | POLD1 | P28340 | 1/20 | 0.40 |
| ▸ | TK1 | P04183 | 1/20 | 0.36 |
| ▸ | DTYMK | P23919 | 2/20 | 0.34 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.33 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.33 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25753928 | 1.00 | POLB (0.40) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL22327094 | 0.93 | FUT5 (0.40) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL20810934 | 0.93 | FUT5 (0.40) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL22327095 | 0.93 | FUT5 (0.40) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL25753565 | 0.90 | POLB (0.36) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL24972764 | 0.89 | POLB (0.44) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL22327272 | 0.89 | POLB (0.39) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL22327117 | 0.88 | POLB (0.48) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL22327114 | 0.88 | POLB (0.48) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL22327289 | 0.88 | POLB (0.48) | POLBPOLA1POLD1TK1DTYMK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-17 | — | — | US | disclosed |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | POLB 2/4885POLA1 37/4885POLD1 127/4885 |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | POLB 2/4885POLA1 37/4885POLD1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.